A. Kurtaran

发表

Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.

Georgios Karanikas, Kurt Kletter, G. Karanikas, 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

W. Scheithauer, P. Valent, P. Angelberger, 1994 .

An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis

W. Schima, P. Speiser, I. Virgolini, 2000, American Journal of Gastroenterology.

Combined transmission and 99mTc-sestamibi emission tomography for localization of mediastinal parathyroid glands

K. Kaczirek, B. Niederle, G. Prager, 2003, Nuklearmedizin.

Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide

W. Scheithauer, I. Virgolini, M. Raderer, 1999 .

11 C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer

R. Pötter, M. Mitterhauser, B. Djavan, 2006 .

New trends in peptide receptor radioligands.

P. Angelberger, I. Virgolini, S. Li, 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

In vitro and in vivo studies of three radiolabelled somatostatin analogues:123I-Octreotide (OCT),123I-Tyr-3-OCT and111In-TIRA-d-Phe-1-OCT

W. Scheithauer, H. Eichler, P. Valent, 1996, European Journal of Nuclear Medicine.

Comparative somatostatin receptor scintigraphy using in-111-DOTA-lanreotide and in-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy.

P. Angelberger, I. Virgolini, S. Li, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993 to 1998.

W. Scheithauer, H. Vierhapper, P. Angelberger, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vasoactive intestinal peptide receptor scintigraphy.

W. Scheithauer, P. Valent, P. Angelberger, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[The thyroid gland in old age : Physiology and pathology].

A. Kurtaran, C. Tugendsam, 2020, Wiener medizinische Wochenschrift.

[Current controversies in risk-adapted therapy in differentiated thyroid cancer: Is less (therapy) really more?]

A. Kurtaran, C. Tugendsam, B. Schmoll-Hauer, 2019, Wiener medizinische Wochenschrift.

Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide

W. Scheithauer, I. Virgolini, M. Raderer, 1999, American Journal of Gastroenterology.

Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo.

W. Scheithauer, I. Virgolini, C. Müller, 2000, International journal of oncology.

Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type

U. Jäger, A. Chott, I. Virgolini, 2001, British Journal of Cancer.

Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.

C. Herold, P. Angelberger, B. Niederle, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

FDG-PET in adrenocortical carcinoma.

G. Karanikas, H. Vierhapper, R. Dudczak, 2001, Cancer biotherapy & radiopharmaceuticals.

Focal Liver Lesions: Receptor Scintigraphy for Differential Diagnosis

A. Kurtaran, O. Kienast, 2003 .

18F-fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver.

W. Schima, I. Virgolini, C. Müller, 2000, Liver.

Distinction between hepatic focal nodular hyperplasia and malignant liver lesions using technetium-99m-galactosyl-neoglycoalbumin.

P. Angelberger, I. Virgolini, C. Müller, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Comparison of Dual Energy X-Ray Absorptiometry of the Proximal Femur with Morphologic Data

F. Kainberger, S. Youssefzadeh, P. Hübsch, 1992, Acta radiologica.

Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy.

P. Angelberger, S. Li, C. Pirich, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of human somatostatin receptor subtype 3 in pancreatic cancer in vitro and in vivo.

W. Scheithauer, I. Virgolini, M. Raderer, 1998, Journal of the National Cancer Institute.

Modified LDL decreases the binding of prostaglandin E2, I2, and E1 onto monocytes in patients with peripheral vascular disease.

I. Virgolini, F. Rauscha, S. Li, 1997, Arteriosclerosis, thrombosis, and vascular biology.

123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.

W. Scheithauer, P. Valent, P. Angelberger, 1996, Nuclear medicine and biology.

Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.

W. Scheithauer, P. Angelberger, I. Virgolini, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Functional aspects of silent ureteral stones investigated with MAG-3 renal scintigraphy

C. Türk, A. Kurtaran, Christopher Springer, 2014, BMC Urology.

Receptor Imaging in Oncology

A. Kurtaran, 1999 .

Survival after intrauterine myocardial infarction: noninvasive assessment of myocardial perfusion with 99mTc-Sestamibi scintigraphy.

U. Salzer-Muhar, R. Birnbacher, S. Kuhle, 2000, American journal of perinatology.

Experience with indium-111 and yttrium-90-labeled somatostatin analogs.

P. Angelberger, I. Virgolini, S. Li, 2002, Current pharmaceutical design.

Occurrence of a pulmonary carcinoid following allogeneic stem cell transplantation for chronic myelogenous leukemia: a case report

F. Kainberger, G. Dekan, M. Raderer, 2003, Annals of Hematology.

Malignancy in slow motion: diagnosis of biochemically apparent, but otherwise occult persistent disease 21 years after resection of a carcinoid tumour of the terminal ileum.

M. Raderer, G. Oberhuber, A. Kurtaran, 2001, Scandinavian journal of gastroenterology.

Somatostatin receptor scintigraphy in primary cutaneous T‐ and B‐cell lymphomas

A. Chott, F. Trautinger, R. Knobler, 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

"MAURITIUS": tumour dose in patients with advanced carcinoma.

P. Angelberger, I. Virgolini, P. Smith-Jones, 1999, Italian journal of gastroenterology and hepatology.

Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.

W. Scheithauer, P. Angelberger, B. Niederle, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Value of Adrenal Imaging in Adrenal Surgery

K. Kaczirek, B. Niederle, G. Heinz-Peer, 2005 .

Combined use of 111In-DTPA-D-Phe-1-octreotide (OCT) and 123I-vasoactive intestinal peptide (VIP) in the localization diagnosis of medullary thyroid carcinoma (MTC).

P. Angelberger, B. Niederle, I. Virgolini, 1996, Nuclear medicine and biology.

Multicenter evaluation of carbon-II acetate pet imaging in men with PSA progression following radical prostatectomy

M. Marberger, B. Djavan, A. Kurtaran, 2003 .

Visualization of intestinal splenosis by somatostatin receptor scintigraphy.

W. Schima, I. Virgolini, K. Kaserer, 1998 .

VISUALIZATION OF INTESTINAL SPLENOSIS BY SOMATOSTATIN RECEPTOR SCINTIGRAPHY

W. Schima, I. Virgolini, K. Kaserer, 1998, American Journal of Gastroenterology.

Absence of Therapeutic Efficacy of the Somatostatin Analogue Lanreotide in Advanced Primary Hepatic Cholangiocellular Cancer and Adenocarcinoma of the Gallbladder Despite In Vivo SomatostatinReceptor Expression

W. Scheithauer, I. Virgolini, M. Raderer, 2002, Scandinavian journal of gastroenterology.

Vasoactive intestinal peptide and somatostatin receptor scintigraphy for differential diagnosis of hepatic carcinoid metastasis.

R. Prokesch, B. Niederle, I. Virgolini, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Primary MALT-lymphoma of the liver: multimodality imaging.

S. Mehrain, A. Ba-Ssalamah, W. Schima, 2003, Critical reviews in computed tomography.

Improved Quality of Life in Patients Treated with Peptide Radionuclides

M. Uffmann, P. Angelberger, I. Virgolini, 2011, World journal of nuclear medicine.

Technetium-99m-galactosyl-neoglycoalbumin combined with iodine-123-Tyr-(A14)-insulin visualizes human hepatocellular carcinomas.

W. Scheithauer, P. Angelberger, C. Müller, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Different Response to the Long-Acting Somatostatin Analogues Lanreotide and Octreotide in a Patient with a Malignant Carcinoid

W. Scheithauer, M. Raderer, G. Oberhuber, 2001, Oncology.

Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

W. Scheithauer, P. Valent, P. Angelberger, 1994, The New England journal of medicine.

New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy.

P. Angelberger, B. Niederle, I. Virgolini, 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

123I-labelled vasoactive intestinal peptide receptor scintigraphy in patients with colorectal cancer.

W. Scheithauer, P. Angelberger, I. Virgolini, 1998, British Journal of Cancer.

Inhalation scintigraphy with iodine-123-labeled interferon gamma-1b: pulmonary deposition and dose escalation study in healthy volunteers.

H. Eichler, P. Valent, P. Angelberger, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Minimally invasive open parathyroidectomy in an endemic goiter area: a prospective study.

C. Czerny, C. Bieglmayer, B. Niederle, 2001, Archives of surgery.

Impact of localization studies on feasibility of minimally invasive parathyroidectomy in an endemic goiter region.

C. Czerny, K. Kaczirek, B. Niederle, 2003, Journal of the American College of Surgeons.

‘Suppressed’ Double Adenoma – A Rare Pitfall in Minimally Invasive Parathyroidectomy

G. Zettinig, B. Niederle, G. Prager, 2002, Hormone Research in Paediatrics.

Scintigraphic imaging of the adrenal glands.

B. Shapiro, A. Kurtaran, T. Traub, 2002, European journal of radiology.

Case 2: myocardial metastases from a carcinoid tumor.

M. Raderer, G. Oberhuber, A. Kurtaran, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Paroxysmal hypertension during micturition.

C. Pirich, A. Kurtaran, C. Kratzik, 2004, American journal of hypertension.

Value of combined XCT/SPECT technology for avoiding false positive planar 123I-MIBG scintigraphy

F. Kainberger, B. Niederle, R. Dudczak, 2004, Nuklearmedizin.

Indium-111-DTPA-D-Phe-1-octreotide and technetium-99m-(V)-dimercaptosuccinic acid scanning in the preoperative staging of medullary thyroid carcinoma.

C. Czerny, W. Schima, P. Angelberger, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Retention of iodine-131 in respiratory tract in a patient with papillary thyroid carcinoma after radionuclide therapy: a rare false-positive finding.

R. Dudczak, A. Kurtaran, O. Kienast, 2003, Thyroid : official journal of the American Thyroid Association.

Pancreatic Imaging: The Value for Surgery of Neuroendocrine Pancreatic Tumors

W. Schima, B. Niederle, A. Kurtaran, 2009 .

Mortality of patients with pulmonary embolism.

A. Bankier, M. Holzer, M. Müllner, 2002, Wiener klinische Wochenschrift.

Atypical focal nodular hyperplasia of the liver: imaging features of nonspecific and liver-specific MR contrast agents.

K. Linnau, T. Helbich, A. Ba-Ssalamah, 2002, AJR. American journal of roentgenology.

Post-treatment imaging of liver tumours

T. Gruenberger, A. Ba-Ssalamah, W. Schima, 2007, Cancer imaging : the official publication of the International Cancer Imaging Society.

Invited commentary to: „Scintigraphic and intraoperative scintimetric localization of an ectopic parathyroid adenoma with Tc-99m Tetrofosmin and Tc-99m Sestamibi“

A. Kurtaran, 1998, Acta Chirurgica Austriaca.

111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung.

W. Schima, I. Virgolini, M. Raderer, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy.

P Hübsch, M Peck-Radosavljevic, P. Valent, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiation Exposure around Patients after 201Tl-Myocardial Scintigraphy

I. Virgolini, A. Kurtaran, E. Havlik, 1997 .

Radiation doses deriving from patients undergoing 111In-DTPA-d-Phe-1-octreotide scintigraphy

H. Bergmann, B. Niederle, I. Virgolini, 1997, European Journal of Nuclear Medicine.

Radiation Exposure near of Patients after Administration of 99mTc-Sestamibi

B. Niederle, I. Virgolini, A. Kurtaran, 1997 .

Radiation Exposure around Patients after Administration of99mTc-DPD

A. Kurtaran, E. Havlik, J. Preitfellner, 1995 .

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results

W. Scheithauer, O. Hoffmann, I. Virgolini, 1999, British Journal of Cancer.

11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

Richard Pötter, Markus Mitterhauser, Bob Djavan, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of four rapid D-Dimer tests for diagnosis of pulmonary embolism.

I. Virgolini, A. Kurtaran, A. Hamwi, 1996, Thrombosis research.

111In-DOTA-dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study

W. Schima, P. Angelberger, I. Virgolini, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type.

A. Chott, J. Drach, I. Virgolini, 1999, Journal of the National Cancer Institute.

Iodine-123-vasoactive intestinal peptide receptor scanning in patients with pancreatic cancer.

W. Scheithauer, P. Angelberger, I. Virgolini, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Aktuelle Diskussion zur risikoadaptierten Therapie des differenzierten Schilddrüsenkarzinoms: Ist weniger (Therapie) wirklich mehr?

A. Kurtaran, C. Tugendsam, B. Schmoll-Hauer, 2019, Wiener Medizinische Wochenschrift.